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Deregulation ofmicroRNAs in dystrophicmuscle highlights their importance inmuscle homeostasis. A recent
study in Cell Metabolism (Cacchiarelli et al., 2010) shows that the presence of functional dystrophin is
required for NO-dependent nitrosylation of the HDAC2 repressor and subsequent activation of a group of
microRNAs required for muscle function.In response to skeletal muscle injury,
satellite cells, quiescent muscle progen-
itor cells that reside along the basal
lamina of the muscle fiber, are activated
to repair the damaged tissue. For muscle
regeneration to be sustainable, a subpop-
ulation of these activated satellite cells
must also maintain their progenitor status
and return to quiescence (Buckingham
and Montarras, 2008). Duchenne mus-
cular dystrophy (Cossu and Sampaolesi,
2007) is marked by the absence of
the structural protein dystrophin, resulting
in a weakened sarcolemma, oxidative
stress, and persistent muscle damage.
This results in chronic muscle regenera-
tion and unsustainable activation of satel-
lite cells, inflammation of muscle tissue
by infiltration of immune cells, and the
eventual replacement of myofibers with
fibrotic or adipose tissue. This monoge-
netic condition, which affects 1 in 3500
boys, leads to progressive weakness
and eventual death mainly due to respira-
tory failure. Inactivation of the microRNA
pathway in the muscle lineage results in
perinatal lethality due to skeletal muscle
hypoplasia, highlighting their essential
role in muscle homeostasis. MicroRNAs
have been implicated in skeletal muscle
disorders, response to injury, and growth
(Crist et al., 2009; Eisenberg et al., 2007;
Greco et al., 2009; Williams et al., 2009a,
2009b). In their recent paper describing
deregulated microRNAs in dystrophic
muscle, Cacchiarelli et al. (2010) demon-
strate that the NO signaling pathway,
coordinated by the dystrophin-associ-
ated protein complex, is responsible for
the direct regulation of a subset of micro-
RNAs, while the chronic activation of
satellite cells and infiltration by immune
cells account for increases in expression
of other microRNAs (Figure 1).To identify microRNAs that are directly
dependent on the presence of dystro-
phin, the authors used an exon skipping
strategy to restore functional dystrophin
to the dystrophic muscle of the mdx
mouse, a model of Duchenne muscular
dystrophy, and profiled microRNAs 1
month after treatment. Some microRNAs,
such as the muscle-specific miR-1, miR-
133, as well as the nonspecific miR-29,
are downregulated in dystrophic muscle
and return to normal levels after partial
restoration of dystrophin expression. The
authors demonstrate that this class of
miRNAs are regulated in part by chro-
matin modifications brought about by
HDAC2 nitrosylation by the NO signaling
pathway, which is repressed in the
absence of dystrophin (Figure 1). Using
chromatin immunoprecipitation, they
demonstrate that in mdx mice HDAC2 is
bound to promoters of miR-1 and miR-
29, in keeping with their observed repres-
sion. Importantly, when the authors
directly injected the NO-donor nitroglyc-
erin intomdxmuscle, HDAC2was nitrosy-
lated to wild-type levels and released
from the promoters of NO-dependent
microRNAs, and the expression of these
microRNAs was restored to wild-type
levels.
Downregulated microRNAs may con-
tribute to the dystrophic pathology by
increased protein expression of their
natural targets. The authors identify the
mRNA for glucose-6-phosphate dehydro-
genase (G6PD), a cytosolic enzyme that
regulates the production of antioxidant
molecules, as a direct target of miR-1.
Downregulation of miR-1 in mdx mice
results in increased levels of G6PD.
Through NADPH production, this impacts
NADPH oxidase, which is higher in
dystrophic muscle, resulting in increasedCell Metabolism 12,oxidative stress. Electroporation of miR-1
expression plasmids in mdx dystrophic
muscle returned G6PD levels to normal;
however, the effect of this treatment on
regeneration was not reported. In another
example of a deregulated, NO-dependent
microRNA, the authors demonstrate that
miR-29 downregulation in mdx mice con-
tributes to disease progression, through
the resulting overproduction of miR-29
target proteins collagen (Col1A1) and
elastin (Eln), associated with fibrosis (Fig-
ure 1), as also seen in myocardial infarc-
tion (van Rooij et al., 2008). Electropora-
tion of miR-29 expression plasmids into
mdx dystrophic muscle reduced levels of
fibrosis.
In contrast, other microRNAs such as
miR-206, which is closely related to
miR-1, are upregulated in dystrophic
muscle (Figure 1) and are not affected
by the partial restoration of dystrophin
(Cacchiarelli et al., 2010). Unlike the NO-
dependent microRNAs, HDAC2 did not
bind to the promoter region of the gene.
The authors demonstrate that miR-206 is
present in the immature, regenerating
muscle of the mdx mouse, and therefore
is unlikely to be linked to the dystrophin/
NO pathway. In dystrophic muscle,
satellite cells are chronically activated to
produce new muscle fibers. The authors
show that the elevated levels of miR-206
will repress Pax7 (Cacchiarelli et al.,
2010), a transcription factor expressed in
satellite cells, which must be silenced for
differentiation to proceed, as shown for
miR-27 regulation of Pax3 (Crist et al.,
2009). It is not yet clear whether the
elevated level of miR-206 in dystrophic
muscle has a salutary role, contributing
to muscle differentiation by timely down-
regulation of Pax7, or is deleterious,
leading to depletion of the pool ofNovember 3, 2010 ª2010 Elsevier Inc. 425
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Figure 1. A Schema of Dystrophic Muscle
MicroRNAs deregulated by loss of dystrophin/NO sig-
naling, are illustrated in black and are associated with
oxidative stress of the muscle fiber and increased deposi-
tion of collagen and elastin, a feature of fibrosis (blue).
Additional microRNAs are deregulated due to chronic acti-
vation of satellite cells (red) or infiltration of granulocytes
(green).
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turely downregulating Pax7. It would
therefore be interesting to determine
if miR-206 null mice in an mdx back-
ground exhibit earlier symptoms of
muscular dystrophy, as was recently
shown in the mouse model of ALS
(Williams et al., 2009b). Finally, other
microRNAs, such as the inflammatory
microRNA miR-223, are upregulated
in dystrophic muscle, probably as
a consequence of inflammation and
invasion of granulocytes (Figure 1).
Their expression returned to normal
levels after exon skipping restored
dystrophin, due to the consequent
reduction of inflammation (Cacchiar-
elli et al., 2010).
These and other studies begin
to reveal the complexity and impor-
tance of microRNA regulation of tis-
sue homeostasis. The identification
of microRNAs deregulated in dystro-
phic muscle increases possible thera-
peutic interventions that could be
envisioned to support strategies to
restore dystrophin expression. Future
studies should address whether or
not the deregulated miRNA contrib-
utes to disease progression, as is
the case for downregulated miR-29,
with consequent increase of collagen
and elastin, associated with fibrosis
(Cacchiarelli et al., 2010; van Rooij
et al., 2008), or downregulated
miR-1, with consequent upregulation
of G6PD, associated with increased
oxidative stress. Mimics for these
microRNAs, if delivered stably, maybe a therapeutic intervention for the
fibrosis and oxidative stress that con-
tribute tomuscle weakening. Upregulated
microRNAs in Duchenne muscular dys-
trophy, that contribute to the progression426 Cell Metabolism 12, November 3, 2010 ªof disease, would be obvious therapeutic
targets. Antisense ‘‘antagomiR’’ tech-
nology (Krutzfeldt et al., 2005), based on
chemically modified antisense oligonu-
cleotides, holds remarkable promise to2010 Elsevier Inc.provide long-lasting inhibition of
microRNAs in multiple tissues, includ-
ing skeletal muscle, following intrave-
nous administration in vivo.
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